Rindopepimut

Identification

Name
Rindopepimut
Accession Number
DB05374  (DB05612)
Type
Small Molecule
Groups
Investigational
Description

Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.

Synonyms
  • Rintega
External IDs
ALT-110 / PF-04948568
Categories
UNII
K3L4X0501F
CAS number
1108208-65-6
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in brain cancer.

Pharmacodynamics
Not Available
Mechanism of action

CDX-110 is an investigational immunotherapy that targets the tumor specific molecule EGFRvIII, a functional variant of the epidermal growth factor receptor (EGFR), which is a protein that has been well validated as a target for cancer therapy. This particular variant, EGFRvIII occurs in about 40 percent of Glioblastoma Multiforme (GBM) patients. It was discovered in a collaborative effort between Dr. Bert Vogelstein and Dr Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Unlike EGFR, EGFRvIII is not present in normal tissues, suggesting this target will enable the development of a tumor-specific therapy for cancer patients. Furthermore, EGFRvIII is a transforming oncogene that can directly contribute to cancer cell growth. While originally discovered in GBM, the most common and aggressive form of brain cancer, the expression of EGFRvIII has also been observed in various other cancers such as breast, ovarian, metastatic prostate, colorectal, and head & neck cancers. Celldex has exclusive rights to EGFRvIII vaccines and is pursuing the development of CDX-110 for GBM therapy, as well as in other cancers through additional clinical studies.

TargetActionsOrganism
UEpidermal growth factor receptorNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Rindopepimut.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Rindopepimut.Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Rindopepimut.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Rindopepimut.Experimental, Illicit
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Rindopepimut.Approved
AbciximabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Abciximab.Approved
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Rindopepimut.Investigational
AbituzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Abituzumab.Investigational
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Rindopepimut.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Rindopepimut.Approved
AdecatumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Adecatumumab.Investigational
AdefovirThe risk or severity of adverse effects can be increased when Adefovir is combined with Rindopepimut.Investigational
AducanumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Aducanumab.Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Rindopepimut.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Rindopepimut.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Rindopepimut.Experimental, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Rindopepimut.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rindopepimut.Approved, Investigational
AlicaforsenThe risk or severity of adverse effects can be increased when Alicaforsen is combined with Rindopepimut.Investigational
AlirocumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Alirocumab.Approved
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Rindopepimut.Approved
AmatuximabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rindopepimut.Approved
AMG 108The therapeutic efficacy of Rindopepimut can be decreased when used in combination with AMG 108.Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Rindopepimut.Approved, Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Rindopepimut.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Rindopepimut.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Rindopepimut.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Rindopepimut.Investigational
AnifrolumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Anifrolumab.Investigational
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Rindopepimut.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Rindopepimut.Approved
ApolizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Apolizumab.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Rindopepimut.Approved, Investigational
AscrinvacumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ascrinvacumab.Investigational
Asfotase AlfaThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Rindopepimut.Investigational
AtezolizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Atezolizumab.Approved, Investigational
AVE9633The therapeutic efficacy of Rindopepimut can be decreased when used in combination with AVE9633.Investigational
AvelumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Avelumab.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with Rindopepimut.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Rindopepimut.Approved
BapineuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bapineuzumab.Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Rindopepimut.Approved, Investigational
BavituximabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Rindopepimut.Approved, Investigational
BectumomabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bectumomab.Investigational
BegelomabThe risk or severity of adverse effects can be increased when Begelomab is combined with Rindopepimut.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Rindopepimut.Approved, Investigational
BelimumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Belimumab.Approved
BenznidazoleThe risk or severity of adverse effects can be increased when Benznidazole is combined with Rindopepimut.Approved, Investigational
BesilesomabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Besilesomab.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Rindopepimut.Approved, Vet Approved
BevacizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bevacizumab.Approved, Investigational
BIIB015The therapeutic efficacy of Rindopepimut can be decreased when used in combination with BIIB015.Investigational
BimagrumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bimagrumab.Investigational
BivatuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bivatuzumab.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Rindopepimut.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with Rindopepimut.Approved, Investigational
BlosozumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Blosozumab.Investigational
BococizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Bococizumab.Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Rindopepimut.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Briakinumab is combined with Rindopepimut.Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Brodalumab is combined with Rindopepimut.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Rindopepimut.Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Rindopepimut.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Rindopepimut.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Rindopepimut.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with Rindopepimut.Approved, Investigational
CaplacizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Caplacizumab.Investigational
Capromab pendetideThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Capromab pendetide.Approved
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with Rindopepimut.Approved
CarlumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Carlumab.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Rindopepimut.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Rindopepimut.Experimental
CatumaxomabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Catumaxomab.Approved, Investigational, Withdrawn
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Rindopepimut.Approved
CetuximabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Rindopepimut.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Rindopepimut.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Rindopepimut.Approved
CixutumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Cixutumumab.Investigational
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Rindopepimut.Approved, Investigational
ClazakizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Clazakizumab.Investigational
ClenoliximabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Clenoliximab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Rindopepimut.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Rindopepimut.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Rindopepimut.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Rindopepimut.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Rindopepimut.Approved, Investigational
Coltuximab ravtansineThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Coltuximab ravtansine.Investigational
ConatumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Conatumumab.Investigational
ConcizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Concizumab.Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Rindopepimut.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Rindopepimut.Experimental
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with Rindopepimut.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Rindopepimut.Approved, Investigational
CR002The therapeutic efficacy of Rindopepimut can be decreased when used in combination with CR002.Investigational
CrenezumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Crenezumab.Investigational
CrotedumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Crotedumab.Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Rindopepimut.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Rindopepimut.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Rindopepimut.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Rindopepimut.Approved, Investigational
DacetuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Rindopepimut.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with Rindopepimut.Approved, Investigational
DalotuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Daratumumab.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with Rindopepimut.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Rindopepimut.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Rindopepimut.Approved, Investigational
DemcizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Demcizumab.Investigational
DenosumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with Rindopepimut.Investigational
DepatuxizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Depatuxizumab.Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Rindopepimut.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Rindopepimut.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Rindopepimut.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Rindopepimut.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Rindopepimut.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Rindopepimut.Vet Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Rindopepimut.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Rindopepimut.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Rindopepimut.Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Rindopepimut.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Rindopepimut.Approved, Investigational
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rindopepimut.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with Rindopepimut.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with Rindopepimut.Approved, Investigational
DulaglutideThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Dulaglutide.Approved, Investigational
DuligotuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Duligotuzumab.Investigational
DupilumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Durvalumab.Approved, Investigational
DusigitumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Dusigitumab.Investigational
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Rindopepimut.Approved, Investigational
EdrecolomabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Edrecolomab.Experimental, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Efalizumab is combined with Rindopepimut.Approved, Investigational
EldelumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Eldelumab.Investigational
ElotuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Emibetuzumab.Investigational
EmicizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Emicizumab.Approved, Investigational
EnokizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Enokizumab.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Rindopepimut.Approved
EpratuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Rindopepimut.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Rindopepimut.Approved
ErenumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Erenumab.Approved, Investigational
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with Rindopepimut.Approved, Investigational
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Rindopepimut.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rindopepimut.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Rindopepimut.Approved, Investigational
EtaracizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Etaracizumab.Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Rindopepimut.Approved
EtrolizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Rindopepimut.Approved
EvolocumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ficlatuzumab.Investigational
FigitumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Figitumumab.Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Rindopepimut.Approved, Investigational
FirategrastThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Firategrast.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Rindopepimut.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Rindopepimut.Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Rindopepimut.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Rindopepimut.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Rindopepimut.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Rindopepimut.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Rindopepimut.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Rindopepimut.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Rindopepimut.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Rindopepimut.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Rindopepimut.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Rindopepimut.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Rindopepimut.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rindopepimut.Approved
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Rindopepimut.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Rindopepimut.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rindopepimut.Approved
FontolizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Rindopepimut.Approved, Investigational, Withdrawn
FremanezumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Fremanezumab.Investigational
FresolimumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Fulranumab.Investigational
GaliximabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with Rindopepimut.Approved, Investigational
GanitumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ganitumab.Investigational
GantenerumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Gantenerumab.Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Rindopepimut.Approved
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Rindopepimut.Approved, Investigational
GevokizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Gevokizumab.Investigational
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Rindopepimut.Approved, Investigational
Glembatumumab vedotinThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Glembatumumab vedotin.Investigational
GlimepirideThe risk or severity of adverse effects can be increased when Glimepiride is combined with Rindopepimut.Approved
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Rindopepimut.Approved
GS 0573The risk or severity of adverse effects can be increased when GS 0573 is combined with Rindopepimut.Investigational
GuselkumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Guselkumab.Approved, Investigational
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Rindopepimut.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Rindopepimut.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Rindopepimut.Investigational
Human C1-esterase inhibitorThe risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Rindopepimut.Approved
Human cytomegalovirus immune globulinThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Human cytomegalovirus immune globulin.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Rindopepimut.Approved, Vet Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with Rindopepimut.Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Rindopepimut.Investigational
IbalizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ibalizumab.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Rindopepimut.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Rindopepimut.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Rindopepimut.Approved, Investigational
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with Rindopepimut.Approved
IdarucizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Idarucizumab.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with Rindopepimut.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with Rindopepimut.Approved
IGN311The therapeutic efficacy of Rindopepimut can be decreased when used in combination with IGN311.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Rindopepimut.Approved
IMC-1C11The therapeutic efficacy of Rindopepimut can be decreased when used in combination with IMC-1C11.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Rindopepimut.Approved, Investigational
Immune Globulin HumanThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Immune Globulin Human.Approved, Investigational
InclacumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Inclacumab.Investigational
Indium In-111 satumomab pendetideThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Indium In-111 satumomab pendetide.Approved, Withdrawn
InebilizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Inebilizumab.Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Rindopepimut.Approved
Inotuzumab ozogamicinThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Inotuzumab ozogamicin.Approved, Investigational
IntetumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Intetumumab.Investigational
IPH 2101The therapeutic efficacy of Rindopepimut can be decreased when used in combination with IPH 2101.Investigational
IpilimumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ipilimumab.Approved
IratumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Iratumumab.Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Rindopepimut.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Rindopepimut.Investigational
IxekizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ixekizumab.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Rindopepimut.Approved, Investigational, Nutraceutical
LabetuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Lampalizumab.Investigational
LandogrozumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Landogrozumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Rindopepimut.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Rindopepimut.Approved
LerdelimumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Lerdelimumab.Investigational
LexatumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Lexatumumab.Investigational
LigelizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ligelizumab.Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Rindopepimut.Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with Rindopepimut.Approved, Investigational
Lorvotuzumab mertansineThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Lorvotuzumab mertansine.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Rindopepimut.Approved
LucatumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Lucatumumab.Investigational
LumiliximabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Lumiliximab.Investigational
MatuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Matuzumab.Investigational
MavrilimumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Mavrilimumab.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Rindopepimut.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with Rindopepimut.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Rindopepimut.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Rindopepimut.Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Rindopepimut.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Rindopepimut.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Rindopepimut.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Rindopepimut.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rindopepimut.Approved, Vet Approved
MilatuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Milatuzumab.Investigational
Mirvetuximab SoravtansineThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Rindopepimut.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with Rindopepimut.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Rindopepimut.Investigational
MogamulizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Mogamulizumab.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Rindopepimut.Approved, Vet Approved
MotavizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Motavizumab.Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Rindopepimut.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Rindopepimut.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rindopepimut.Approved
MYO-029The therapeutic efficacy of Rindopepimut can be decreased when used in combination with MYO-029.Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Rindopepimut.Approved, Investigational
Naptumomab EstafenatoxThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Naptumomab Estafenatox.Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Rindopepimut.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Rindopepimut.Investigational
NebacumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Nebacumab.Experimental
NecitumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Necitumumab.Approved, Investigational
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with Rindopepimut.Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with Rindopepimut.Approved, Investigational
NimotuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Nimotuzumab.Investigational
NivolumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Rindopepimut.Approved, Investigational
OcrelizumabThe therapeutic efficacy of Ocrelizumab can be decreased when used in combination with Rindopepimut.Approved, Investigational
OfatumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Olaratumab.Approved, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Rindopepimut.Investigational
OlokizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Olokizumab.Investigational
OmalizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Omalizumab.Approved, Investigational
OnartuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Otelixizumab.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Rindopepimut.Approved, Investigational
OzanezumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ozanezumab.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Rindopepimut.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with Rindopepimut.Approved, Investigational
PalivizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with Rindopepimut.Approved, Investigational
PaquinimodThe risk or severity of adverse effects can be increased when Paquinimod is combined with Rindopepimut.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Rindopepimut.Approved
PatritumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Patritumab.Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with Rindopepimut.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Rindopepimut.Approved, Investigational
PembrolizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Rindopepimut.Approved, Investigational
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Rindopepimut.Approved, Investigational
PertuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Rindopepimut.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with Rindopepimut.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Rindopepimut.Approved, Investigational
Polatuzumab VedotinThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Polatuzumab Vedotin.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Rindopepimut.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with Rindopepimut.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Rindopepimut.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Rindopepimut.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rindopepimut.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rindopepimut.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Rindopepimut.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Rindopepimut.Approved, Experimental, Investigational
PRO 140The therapeutic efficacy of Rindopepimut can be decreased when used in combination with PRO 140.Investigational
PRO-542The therapeutic efficacy of Rindopepimut can be decreased when used in combination with PRO-542.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Rindopepimut.Approved, Investigational
R1507The therapeutic efficacy of Rindopepimut can be decreased when used in combination with R1507.Investigational
RacotumomabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Raxibacumab.Approved
ReslizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Reslizumab.Approved, Investigational
RI 624The therapeutic efficacy of Rindopepimut can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of Rindopepimut can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Rindopepimut.Approved, Investigational
RilotumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Rindopepimut.Approved
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Rindopepimut.Approved
RobatumumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Robatumumab.Investigational
RomosozumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Romosozumab.Investigational
RontalizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Rontalizumab.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with Rindopepimut.Approved
Sacituzumab govitecanThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Sacituzumab govitecan.Investigational
SarilumabThe risk or severity of infection can be increased when Sarilumab is combined with Rindopepimut.Approved, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Rindopepimut.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Rindopepimut.Investigational
SeocalcitolThe risk or severity of adverse effects can be increased when Seocalcitol is combined with Rindopepimut.Experimental, Investigational
SeribantumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Seribantumab.Investigational
SibrotuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Sibrotuzumab.Investigational
SiltuximabThe risk or severity of adverse effects can be increased when Siltuximab is combined with Rindopepimut.Approved, Investigational
SiplizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Siplizumab.Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Rindopepimut.Approved, Investigational
SirukumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Sirukumab.Investigational
SolanezumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Solanezumab.Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Rindopepimut.Approved, Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with Rindopepimut.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Rindopepimut.Approved, Investigational
SulesomabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Sulesomab.Approved
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with Rindopepimut.Approved, Investigational
SYM001The therapeutic efficacy of Rindopepimut can be decreased when used in combination with SYM001.Investigational
TabalumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tabalumab.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Rindopepimut.Approved, Investigational
TanezumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tanezumab.Investigational
TarextumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tarextumab.Investigational
TB-402The therapeutic efficacy of Rindopepimut can be decreased when used in combination with TB-402.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Technetium Tc-99m arcitumomab.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Rindopepimut.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Rindopepimut.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Rindopepimut.Approved
TeplizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Teplizumab.Investigational
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Rindopepimut.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Rindopepimut.Approved
Tetanus Immune GlobulinThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tetanus Immune Globulin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Rindopepimut.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Rindopepimut.Approved, Investigational
TildrakizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tildrakizumab.Approved, Investigational
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Rindopepimut.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Rindopepimut.Approved, Withdrawn
TNX-901The therapeutic efficacy of Rindopepimut can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with Rindopepimut.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Rindopepimut.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with Rindopepimut.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Rindopepimut.Approved, Investigational
TovetumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tovetumab.Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with Rindopepimut.Approved, Investigational
TralokinumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tralokinumab.Investigational
TrastuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Rindopepimut.Approved, Investigational
TRC105The therapeutic efficacy of Rindopepimut can be decreased when used in combination with TRC105.Investigational
TremelimumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Tremelimumab.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Rindopepimut.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Rindopepimut.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Rindopepimut.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with Rindopepimut.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Rindopepimut.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Rindopepimut.Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Rindopepimut.Approved
VeltuzumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Veltuzumab.Investigational
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with Rindopepimut.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Rindopepimut.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Rindopepimut.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Rindopepimut.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Rindopepimut.Approved, Investigational
VisilizumabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Visilizumab.Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Rindopepimut.Investigational
VolociximabThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Volociximab.Investigational
WortmanninThe risk or severity of adverse effects can be increased when Wortmannin is combined with Rindopepimut.Experimental
XmAb 2513The therapeutic efficacy of Rindopepimut can be decreased when used in combination with XmAb 2513.Investigational
XTL-001The therapeutic efficacy of Rindopepimut can be decreased when used in combination with XTL-001.Investigational
Food Interactions
Not Available

References

General References
  1. Zussman BM, Engh JA: Outcomes of the ACT III Study: Rindopepimut (CDX-110) Therapy for Glioblastoma. Neurosurgery. 2015 Jun;76(6):N17. doi: 10.1227/01.neu.0000465855.63458.0c. [PubMed:25985004]
External Links
PubChem Substance
347910109
Wikipedia
Rindopepimut

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedTreatmentBrain Cancer / Brain Stem Tumors / Pontine Tumors1
Not AvailableNo Longer AvailableNot AvailableRecurrent GBM1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...
Gene Name
EGFR
Uniprot ID
P00533
Uniprot Name
Epidermal growth factor receptor
Molecular Weight
134276.185 Da

Drug created on November 18, 2007 11:24 / Updated on July 02, 2018 18:26